Skip to main content
Nykode Therapeutics ASA logo

Nykode Therapeutics ASA — Investor Relations & Filings

Ticker · NYKD ISIN · NO0010714785 LEI · 254900UKQHWYZJD22017 OL Manufacturing
Open in API
Filings indexed 493 across all filing types
Latest filing 2023-01-09 Investor Presentation
Country NO Norway
Listing OL NYKD

About Nykode Therapeutics ASA

https://nykode.com/

Nykode Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company's core is its proprietary Vaccibody™ technology, a modular platform designed to create targeted vaccines. This technology works by linking antigens to a targeting unit, which delivers them directly to antigen-presenting cells. This mechanism is engineered to induce rapid, potent, and long-lasting T-cell and antibody immune responses. Nykode's development pipeline is focused on generating therapeutics for a range of diseases, with a primary emphasis on oncology and infectious diseases.

Recent filings

Filing Released Lang Actions
Nykode Therapeutics - Presentation at the 41st Annual J.P. Morgan Healthcare Conference
Investor Presentation Classification · 99% confidence The document explicitly states it is a 'Presentation at the 41st Annual J.P. Morgan Healthcare Conference'. This type of material, which is a detailed presentation given to investors at a major industry conference, directly corresponds to the definition of an Investor Presentation (IP). Although it mentions the presentation is attached, the core content is the presentation itself, not just an announcement of its availability, making IP a better fit than RPA, especially given the detailed company and pipeline information provided, which is typical of an investor deck.
2023-01-09 English
Financial calendar
Report Publication Announcement Classification · 99% confidence The document is titled 'Financial calendar' and lists scheduled dates for various corporate events, including 'Quarterly Report', 'Half-yearly Report', 'Annual Report', and 'Annual General Meeting'. This type of forward-looking schedule, detailing future reporting dates, does not fit neatly into the definitions for the reports themselves (10-K, IR, ER, etc.) or the meeting materials (AGM-R). It is a general announcement regarding the company's schedule of corporate actions and reporting releases. Since it is a specific announcement about future events rather than the content of those events, and it doesn't fit other specific categories like DIV, DVA, or MANG, the most appropriate general category for scheduling/calendar information that doesn't fit elsewhere is the fallback category, Regulatory Filings (RNS), as it is an official publication of corporate information.
2022-12-30 English
Nykode Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Report Publication Announcement Classification · 99% confidence The document is a short announcement from Nykode Therapeutics stating that its CEO will present at the '41st Annual J.P. Morgan Healthcare Conference' on a specific date. It provides details about the presentation time and where to access the webcast. This is not a full financial report (like 10-K or IR), nor is it a dividend announcement, earnings release, or management change. It is an announcement about the company's participation in an investor event, which falls under general investor relations communication. Since it is an announcement about an upcoming presentation/event, it is best classified as a Report Publication Announcement (RPA) if the presentation itself is considered a 'report' or 'material' being published/presented, or potentially a Regulatory Filing (RNS) if no other category fits well. Given the context of investor events, RPA is often used for announcements regarding the release or presentation of investor materials. However, since the core content is about *presenting* at a conference, and not announcing the publication of a formal company report, the most fitting category among the specific options is often the general regulatory/investor announcement category, RNS, or if we interpret the presentation itself as a material being released, RPA. Given the options, and that this is a standard announcement about an investor conference presentation, it aligns closely with the intent of announcing corporate activity to investors, which often defaults to RNS if RPA is reserved strictly for announcing the publication of formal reports (like 10-K or IR). Let's re-evaluate RPA: 'Report Publication Announcement (RPA): Announcement regarding the timing, release, or publication of company reports (often stating the report is attached or available on the website).' This announcement is about a presentation, not a formal report publication. Therefore, RNS (General regulatory announcements and fallback category) is the most appropriate fallback for this specific type of investor relations news release that doesn't fit the other specific categories like ER, IP, or DIV.
2022-12-23 English
Nykode Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Investor Presentation Classification · 95% confidence The document is a short press release announcing that Nykode Therapeutics' CEO will present at the 41st Annual J.P. Morgan Healthcare Conference on a specific date. It provides details about the presentation time and a link to access the webcast. This type of announcement, which informs investors about participation in a major industry event (like a conference presentation), is typically classified as an Investor Presentation (IP) announcement or, more broadly, a general regulatory/investor relations communication. Since the document itself is not the presentation slides but the announcement of the presentation, and it doesn't fit the strict definitions of ER, IR, or 10-K, it is best classified as an Investor Presentation (IP) announcement, as the core subject is an upcoming investor-facing presentation. Given the short length and the nature of announcing participation in an external event, it aligns closely with investor relations material dissemination.
2022-12-23 English
Share capital increase from exercise of warrants
Share Issue/Capital Change Classification · 98% confidence The document explicitly states the subject is a "Share capital increase from exercise of warrants." It details the resulting change in share capital (from NOK 2,939,043.09 to NOK 2,946,943.09) and the increase in the number of outstanding shares (by 790,000). This directly relates to a change in the company's capital structure due to the issuance of new shares following warrant exercise. This aligns perfectly with the definition for 'Share Issue/Capital Change' (SHA). It is not a general financing update (CAP) but a specific notification of a capital structure change.
2022-12-22 English
Registration of new share capital
Share Issue/Capital Change Classification · 98% confidence The document explicitly states 'Registration of new share capital' and details the resulting change in the company's share capital (NOK 2,939,043.09, divided into 293,904,309 shares). This directly relates to a change in the company's capital structure following a previous event (exercise of warrants). This aligns perfectly with the definition of 'Share Issue/Capital Change' (SHA), which covers announcements regarding new share issues or capital changes.
2022-12-20 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.